Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Akston Biosciences
Deal Size : Undisclosed
Deal Type : Termination
Details : Akston has reclaimed all rights to AKS-452, a room temperature stable, low-cost, protein subunit COVID-19 vaccine. Akston is continuing its progress to secure Emergency Use Authorization (EUA) in India and has begun working with a new CDMO to produce AKS...
Brand Name : AKS-452
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 07, 2023
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Akston Biosciences
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : rAd26
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Russian Direct Investment Fund
Deal Size : Not Applicable
Deal Type : Not Applicable
Stelis Biopharma Gets CDSCO Nod to Export 50 Million Doses of Sputnik Light Vaccine
Details : Sputnik Light (rAd26) vaccine demonstrates 91.6% efficacy rate against coronavirus, the world’s first registered vaccine against the novel coronavirus infection, is now approved for use in over 50 countries.
Brand Name : Sputnik Light
Molecule Type : Vaccine
Upfront Cash : Not Applicable
December 21, 2021
Lead Product(s) : rAd26
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Russian Direct Investment Fund
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
